Log ud Log ind
Log ud Log ind

ViroGates close to a commercial breakthrough

Morten W. Langer

fredag 20. august 2021 kl. 9:05

The First North company ViroGates may be just two-three months away from an outright sales boom. Swedish drug company Sobi, whose product Anakinra can cure potentially fatal Covid-19 patients, last week submitted an application to the European Medicines Agency (EMA) that could have a huge impact on Virogates.

ViroGates’ commercial success with its corona marker is entirely dependent on Sobi, which has just submitted a marketing application to the EMA.  European approval of Sobi’s product, which can cure very sick Covid-19 patients, is expected as early as October, after which commercial roll-out is expected immediately afterwards.

The link between Sobi and Virogates is as follows:  Sobi’s product Anarkina has been on the market for almost 20 years, and is only used in very sick people.  Due to serious side effects, in the case of Covid-19, the product will only be used in patients who are either very ill or expected to become very ill.

And that’s where ViroGates comes in. ViroGates’ suPAR test can identify those patients who, based on their inflammatory status, are expected to become even sicker. So when Sobi goes out to market Anakinra as a treatment for Covid-19 from October, Sobi’s sales people will simultaneously market and sell ViroGates’ suPAR test.

Virogates’ suPAR test is what is commonly called a biomarker, and while the percentage growth has been strong in recent years, the sales numbers have been small and modest. The successful launch of Anakinra and suPAR could turn that around. “There is no doubt that it will have even commercial significance for us if Sobi’s launch is successful,” says CEO Jacob Knudsen of ViroGates to Financial Weekly.

Sobi’s sales force, which sells only Anarkina and from October also suPAR from Virogates, is ten times larger than the sales force that normally sells and represents Virogates. The details of the application submitted are available on the EMA website, which can be viewed here.

ViroGates hopes that the marketing of suPAR with the new data, will make the many potential hospital customers aware of the opportunities they have to save money by generally using the suPAR test. In popular terms, the test can separate the sheep from the goats, so hospitals quickly send home those patients who do not require here-and-now treatment and who are costing hospitals dearly.

“For a small company like us, this is a great opportunity to gain an additional and invaluable entry point with current and future customers. When you make a living selling biomarkers, it is initially difficult to convince hospitals, but if it can be done in conjunction with a pharmaceutical product, it will be much easier,” Jacob Knudsen estimates.

ViroGates does not generally see itself as a Covid company, but international studies have shown that biomarkers can generally predict whether a patient will develop a serious disease or not, even on arrival in an emergency room. The study found that patients with high inflammation who received Anakinra became significantly less ill than those who received a placebo.

And it is these results, expected to be published soon, that have prompted Sobi to submit an application to the EMA.

ViroGate’s earnings budget for the remainder of 2021 is unlikely to be affected by Sobi’s application to the EMA, as the eventual approval will not take place until October.

Despite continuous losses, the company has maintained that its current capital position is sufficient until the company becomes cash positive.

After the Q1 results, CEO Jakob Knudsen said,  “We are excited to start this year with strong revenue growth and the announcement of a ground-breaking study across 42 hospitals in Greece and Italy within the important field of combatting the COVID-19 disease. Also, we are happy to have welcomed four hospitals in Greece as new clinical routine customers – this holds much promise for the remainder of the year.”

The quarterly report did not disclose any information on the future collaboration with Sobi.  The application to the EMA states that a conclusion on the evaluation can be expected in October and that the drug has been approved in the EU since 2002.

Morten W. Langer

Would you like to read more articles in English? Find them here: Our articles in English

Tilmeld dig vores gratis nyhedsbrev
ØU Bestyrelsesguiden

Få de vigtigste nyheder om praktisk bestyrelsesarbejde, ledelse og strategi i SMV.
Udkommer hver onsdag.

Jeg giver samtykke til, at I sender mig mails med de seneste historier fra Økonomisk Ugebrev. Lejlighedsvis må I gerne sende mig gode tilbud og information om events. Samtidig accepterer jeg ØU’s Privatlivspolitik.

Du kan til enhver tid afmelde dig med et enkelt klik.


Artikler i serien


Controller til centralt projektkontor
Region hovedstaden
Pharma Nord søger en dygtig regnskabsassistent
region syd

Mere fra ØU Ledelse

Log ind

Har du ikke allerede en bruger? Opret dig her.

*Tilbuddet gælder ikke, hvis man har været abonnent indenfor de seneste 6 måneder

Tilmeld dig vores nyhedsbrev

Og modtag ØU’s rapport om Top 40 Ledelseskonsulenter gratis.


Her er de 10 bedste aktier i 2022

Tilbuddet udløber om:

Analyse af og prognoser for Fixed Income (statsrenter og realkreditrenter)

Direkte adgang til opdaterede analyser fra toneangivende finanshuse:

Goldman Sachs


Danske Bank

Morgan Stanley

ABN Amro

Jyske Bank





Merril Lynch 

Direkte adgang til realkreditinstitutternes renteprognoser:


Realkredit Danmark


Analyse og prognoser for kort rente, samt for centralbankernes politikker



Capital Economics

Yardeni – Central Bank Balance Sheet FED Watch Monitor Tool